Leading Mid Corporates 2020

Leading Mid-Corporates of India 2020 E - 41 Experts' View AstraZeneca is a global science-led biopharmaceutical organization supporting the company’s purpose of delivering life changing medicines to patients. We develop medicines, create supporting programs and channel our investments – including those focused on prevention and strengthening health systems – to meet the needs of communities. Bringing forth a legacy of 40 years of bringing science to patients, AstraZeneca focuses on discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three main therapy areas-Oncology, Cardiovascular,Renal&MetabolismandRespiratory coupled with a sophisticated production facility conforming to WHO cGMP norms. Our sustainability strategy is built around three pillars that put health at the heart of our work— beginning with Access to Healthcare. As a global company, we seek to leverage our reach, scale and expertise to effect real change in multiple sustainability issues. AstraZeneca through its flagship programmes – Young Health Programme, Early Action in Diabetes, Healthy Lung and Ganga Godavari Early Cancer Screening Programme – is at the forefront of addressing the unmet needs in Non-Communicable Diseases (NCDs) such as diabetes, heart diseases, asthma & COPD, and cancer. We have a three-pronged approach to making science accessible and sustainable for the society: Access to healthcare: Connecting our business growth to larger positive impact across the society Environmental protection: Reducing our dependence on natural resources Ethics and Transparency: Putting our values at the forefront of decision-making AstraZeneca’s global Health Innovation Hubs network comprises both physical locations and virtual partnerships, and works to solve, scale and showcase innovative and holistic health solutions. Our vision for our Health Innovation Hubs is to create and strengthen partnerships across emerging biomedical clusters – to accelerate innovation, increase healthcare access and improve outcomes for society. Our India Hub focuses on utilising digital technologies, such as Artificial Intelligence (AI) and the Internet of Things (IoT) and gearing them towards alleviating the healthcare burden in India, where 43% of the overall mortality rate is attributed to Non-Communicable Diseases (NCDs). Wehavebeenagileinour responsetotheCOVID-19 outbreak by considering science as our guiding force, putting patients first and always opting for the right thing to do. Amid an unprecedented crisis, our priorities have been to ensure uninterrupted supply of medicines and safeguarding the health of our employees and adjoining communities. Our approach to business continuity planning leverages measures, such as supply processes and operational agility, among others. In order to pursue our Growth Through Innovation strategy in this fast changing healthcare environment, AstraZeneca India constantly leverages the strength of diversity of its people, continuously encouraging alternative ideas, opinion and empowering decision making is the key to embrace and lead this change and hence focused on investing in building a Diverse Workforce and a Culture of Inclusion to harness all this intellectual capital for the growth of the organization. Over the years, we adopted an integrated and consistent approach to treatment, that has proven effective and helped reduce morbidity and mortality of diseases across these areas. Our concerted focus is on relooking at the treatment paradigm of the disease and eliminate the terminal nature of the disease. Within this sphere, we are working to leverage our deep knowledge and capacities to deliver ground-breaking solutions that can transform living. Gagan Singh Country President AstraZeneca Pharma India Ltd. Dun & Bradstreet